ID   ANPRB_HUMAN             Reviewed;        1047 AA.
AC   P20594; B0ZBF2; B0ZBF3; D3DRP3; D3DRP4; O60871; Q4VAK7; Q5TCV2; Q8TA93;
AC   Q9UQ50;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   12-OCT-2022, entry version 226.
DE   RecName: Full=Atrial natriuretic peptide receptor 2;
DE            EC=4.6.1.2 {ECO:0000269|PubMed:26980729};
DE   AltName: Full=Atrial natriuretic peptide receptor type B;
DE            Short=ANP-B;
DE            Short=ANPR-B;
DE            Short=NPR-B;
DE   AltName: Full=Guanylate cyclase B;
DE            Short=GC-B;
DE   Flags: Precursor;
GN   Name=NPR2; Synonyms=ANPRB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ISOFORM LONG).
RC   TISSUE=Brain;
RX   PubMed=2570358; DOI=10.1038/341068a0;
RA   Chang M.S., Lowe D.G., Lewis M., Hellmiss R., Chen E., Goeddel D.V.;
RT   "Differential activation by atrial and brain natriuretic peptides of two
RT   different receptor guanylate cyclases.";
RL   Nature 341:68-72(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=10082481; DOI=10.1161/01.res.84.5.605;
RA   Rehemudula D., Nakayama T., Soma M., Takahashi Y., Uwabo J., Sato M.,
RA   Izumi Y., Kanmatsuse K., Ozawa Y.;
RT   "Structure of the type B human natriuretic peptide receptor gene and
RT   association of a novel microsatellite polymorphism with essential
RT   hypertension.";
RL   Circ. Res. 84:605-610(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Kidney;
RX   PubMed=10073597; DOI=10.1681/asn.v103472;
RA   Hirsch J.R., Meyer M., Maegert H.-J., Forssmann W.-G., Mollerup S.,
RA   Herter P., Weber G., Cermak R., Ankorina-Stark I., Schlatter E.,
RA   Kruhoffer M.;
RT   "cGMP-dependent and -independent inhibition of a K+ conductance by
RT   natriuretic peptides: molecular and functional studies in human proximal
RT   tubule cells.";
RL   J. Am. Soc. Nephrol. 10:472-480(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   LIGAND-BINDING.
RX   PubMed=1660465; DOI=10.1016/s0021-9258(18)54463-x;
RA   Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R., Burnier J.,
RA   Henzel W., Lowe D.G.;
RT   "Extracellular domain-IgG fusion proteins for three human natriuretic
RT   peptide receptors. Hormone pharmacology and application to solid phase
RT   screening of synthetic peptide antisera.";
RL   J. Biol. Chem. 266:23060-23067(1991).
RN   [9]
RP   FUNCTION.
RX   PubMed=1672777; DOI=10.1126/science.1672777;
RA   Koller K.J., Lowe D.G., Bennett G.L., Minamino N., Kangawa K., Matsuo H.,
RA   Goeddel D.V.;
RT   "Selective activation of the B natriuretic peptide receptor by C-type
RT   natriuretic peptide (CNP).";
RL   Science 252:120-123(1991).
RN   [10]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [11]
RP   FUNCTION, VARIANTS AMD1 THR-32; GLY-115; GLU-176; MET-297; CYS-338;
RP   THR-409; GLU-413; CYS-708; TRP-776; CYS-957 AND ALA-959, AND
RP   CHARACTERIZATION OF VARIANTS AMD1 GLY-115; MET-297 AND GLU-413.
RX   PubMed=15146390; DOI=10.1086/422013;
RA   Bartels C.F., Buekuelmez H., Padayatti P., Rhee D.K.,
RA   van Ravenswaaij-Arts C., Pauli R.M., Mundlos S., Chitayat D., Shih L.-Y.,
RA   Al-Gazali L.I., Kant S., Cole T., Morton J., Cormier-Daire V., Faivre L.,
RA   Lees M., Kirk J., Mortier G.R., Leroy J., Zabel B., Kim C.A., Crow Y.,
RA   Braverman N.E., van den Akker F., Warman M.L.;
RT   "Mutations in the transmembrane natriuretic peptide receptor NPR-B impair
RT   skeletal growth and cause acromesomelic dysplasia, type Maroteaux.";
RL   Am. J. Hum. Genet. 75:27-34(2004).
RN   [12]
RP   PHOSPHORYLATION AT SER-513; THR-516; SER-518; SER-523; SER-526 AND THR-529.
RX   PubMed=20977274; DOI=10.1021/bi101700e;
RA   Yoder A.R., Stone M.D., Griffin T.J., Potter L.R.;
RT   "Mass spectrometric identification of phosphorylation sites in guanylyl
RT   cyclase A and B.";
RL   Biochemistry 49:10137-10145(2010).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-232 AND ILE-882.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [14]
RP   INVOLVEMENT IN ECDM, VARIANT ECDM MET-882, AND CHARACTERIZATION OF VARIANT
RP   ECDM MET-882.
RX   PubMed=22870295; DOI=10.1371/journal.pone.0042180;
RA   Miura K., Namba N., Fujiwara M., Ohata Y., Ishida H., Kitaoka T.,
RA   Kubota T., Hirai H., Higuchi C., Tsumaki N., Yoshikawa H., Sakai N.,
RA   Michigami T., Ozono K.;
RT   "An overgrowth disorder associated with excessive production of cGMP due to
RT   a gain-of-function mutation of the natriuretic peptide receptor 2 gene.";
RL   PLoS ONE 7:E42180-E42180(2012).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN SNSK, VARIANTS SNSK PRO-76;
RP   PRO-263 AND CYS-819, AND CHARACTERIZATION OF VARIANTS SNSK PRO-76; PRO-263
RP   AND CYS-819.
RX   PubMed=24001744; DOI=10.1210/jc.2013-2142;
RA   Vasques G.A., Amano N., Docko A.J., Funari M.F., Quedas E.P., Nishi M.Y.,
RA   Arnhold I.J., Hasegawa T., Jorge A.A.;
RT   "Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a
RT   cause of short stature in patients initially classified as idiopathic short
RT   stature.";
RL   J. Clin. Endocrinol. Metab. 98:E1636-E1644(2013).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN SNSK, VARIANTS SNSK CYS-110
RP   AND GLU-417, VARIANT ILE-187, CHARACTERIZATION OF VARIANTS SNSK CYS-110 AND
RP   GLU-417, AND CHARACTERIZATION OF VARIANT ILE-187.
RX   PubMed=24471569; DOI=10.1210/jc.2013-3525;
RA   Amano N., Mukai T., Ito Y., Narumi S., Tanaka T., Yokoya S., Ogata T.,
RA   Hasegawa T.;
RT   "Identification and functional characterization of two novel NPR2 mutations
RT   in Japanese patients with short stature.";
RL   J. Clin. Endocrinol. Metab. 99:E713-E718(2014).
RN   [17]
RP   CHARACTERIZATION OF VARIANT ECDM MET-882.
RX   PubMed=23827346; DOI=10.1016/j.bone.2013.06.024;
RA   Robinson J.W., Dickey D.M., Miura K., Michigami T., Ozono K., Potter L.R.;
RT   "A human skeletal overgrowth mutation increases maximal velocity and blocks
RT   desensitization of guanylyl cyclase-B.";
RL   Bone 56:375-382(2013).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS AMD1 PHE-658; CYS-708; TRP-776 AND ALA-959,
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY,
RP   GLYCOSYLATION, PHOSPHORYLATION, AND MUTAGENESIS OF ASN-24.
RX   PubMed=26980729; DOI=10.1074/jbc.m115.704015;
RA   Dickey D.M., Edmund A.B., Otto N.M., Chaffee T.S., Robinson J.W.,
RA   Potter L.R.;
RT   "Catalytically active guanylyl cyclase b requires endoplasmic reticulum-
RT   mediated glycosylation, and mutations that inhibit this process cause
RT   dwarfism.";
RL   J. Biol. Chem. 291:11385-11393(2016).
RN   [19]
RP   VARIANT AMD1 PHE-658, AND CHARACTERIZATION OF VARIANT AMD1 PHE-658.
RX   PubMed=17652215; DOI=10.1210/jc.2007-1101;
RA   Hachiya R., Ohashi Y., Kamei Y., Suganami T., Mochizuki H., Mitsui N.,
RA   Saitoh M., Sakuragi M., Nishimura G., Ohashi H., Hasegawa T., Ogawa Y.;
RT   "Intact kinase homology domain of natriuretic peptide receptor-B is
RT   essential for skeletal development.";
RL   J. Clin. Endocrinol. Metab. 92:4009-4014(2007).
RN   [20]
RP   VARIANT ECDM CYS-655, AND CHARACTERIZATION OF VARIANT ECDM CYS-655.
RX   PubMed=24057292; DOI=10.1210/jc.2013-2358;
RA   Hannema S.E., van Duyvenvoorde H.A., Premsler T., Yang R.B., Mueller T.D.,
RA   Gassner B., Oberwinkler H., Roelfsema F., Santen G.W., Prickett T.,
RA   Kant S.G., Verkerk A.J., Uitterlinden A.G., Espiner E., Ruivenkamp C.A.,
RA   Oostdijk W., Pereira A.M., Losekoot M., Kuhn M., Wit J.M.;
RT   "An activating mutation in the kinase homology domain of the natriuretic
RT   peptide receptor-2 causes extremely tall stature without skeletal
RT   deformities.";
RL   J. Clin. Endocrinol. Metab. 98:E1988-E1998(2013).
RN   [21]
RP   VARIANT ECDM PRO-488, AND CHARACTERIZATION OF VARIANT ECDM PRO-488.
RX   PubMed=24259409; DOI=10.1002/ajmg.a.36218;
RA   Miura K., Kim O.H., Lee H.R., Namba N., Michigami T., Yoo W.J., Choi I.H.,
RA   Ozono K., Cho T.J.;
RT   "Overgrowth syndrome associated with a gain-of-function mutation of the
RT   natriuretic peptide receptor 2 (NPR2) gene.";
RL   Am. J. Med. Genet. A 164A:156-163(2014).
CC   -!- FUNCTION: Receptor for the C-type natriuretic peptide NPPC/CNP hormone.
CC       Has guanylate cyclase activity upon binding of its ligand. May play a
CC       role in the regulation of skeletal growth.
CC       {ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:1672777,
CC       ECO:0000269|PubMed:24001744, ECO:0000269|PubMed:24471569,
CC       ECO:0000269|PubMed:26980729}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2;
CC         Evidence={ECO:0000269|PubMed:26980729};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24001744,
CC       ECO:0000269|PubMed:26980729}; Single-pass type I membrane protein
CC       {ECO:0000305|PubMed:26980729}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P20594-1; Sequence=Displayed;
CC       Name=Short; Synonyms=NPR-BI;
CC         IsoId=P20594-2; Sequence=VSP_001810;
CC   -!- PTM: Phosphorylated (PubMed:26980729). Phosphorylation of the protein
CC       kinase-like domain is required for full activation by CNP (By
CC       similarity). {ECO:0000250|UniProtKB:P16067,
CC       ECO:0000269|PubMed:26980729}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:26980729}.
CC   -!- DISEASE: Acromesomelic dysplasia 1 (AMD1) [MIM:602875]: A form of
CC       acromesomelic dysplasia, a skeletal disorder characterized by short
CC       stature, very short limbs and hand/foot malformations. The severity of
CC       limb abnormalities increases from proximal to distal with profoundly
CC       affected hands and feet showing brachydactyly and/or rudimentary
CC       fingers (knob-like fingers). AMD1 is an autosomal recessive form
CC       characterized by axial skeletal involvement with wedging of vertebral
CC       bodies. All skeletal elements are present but show abnormal rates of
CC       linear growth. {ECO:0000269|PubMed:15146390,
CC       ECO:0000269|PubMed:17652215, ECO:0000269|PubMed:26980729}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Epiphyseal chondrodysplasia, Miura type (ECDM) [MIM:615923]:
CC       An overgrowth syndrome characterized by tall stature, long hands and
CC       feet with arachnodactyly, macrodactyly of the great toes, scoliosis,
CC       coxa valga and slipped capital femoral epiphysis.
CC       {ECO:0000269|PubMed:22870295, ECO:0000269|PubMed:23827346,
CC       ECO:0000269|PubMed:24057292, ECO:0000269|PubMed:24259409}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Short stature with non-specific skeletal abnormalities (SNSK)
CC       [MIM:616255]: A condition characterized by short stature, defined as a
CC       height less than 2 SD below normal, and no endocrine abnormalities.
CC       {ECO:0000269|PubMed:24001744, ECO:0000269|PubMed:24471569}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform Short]: May be produced at very low levels due
CC       to a premature stop codon in the mRNA, leading to nonsense-mediated
CC       mRNA decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB005647; BAA81737.1; -; Genomic_DNA.
DR   EMBL; AJ005282; CAA06466.1; -; mRNA.
DR   EMBL; AL133410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; EU326311; ACA05920.1; -; Genomic_DNA.
DR   EMBL; EU326311; ACA05921.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58338.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58337.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58339.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58340.1; -; Genomic_DNA.
DR   EMBL; BC023017; AAH23017.1; -; mRNA.
DR   CCDS; CCDS6590.1; -. [P20594-1]
DR   PIR; S05514; OYHUBR.
DR   RefSeq; NP_003986.2; NM_003995.3. [P20594-1]
DR   AlphaFoldDB; P20594; -.
DR   SMR; P20594; -.
DR   BioGRID; 110942; 12.
DR   IntAct; P20594; 3.
DR   STRING; 9606.ENSP00000341083; -.
DR   BindingDB; P20594; -.
DR   ChEMBL; CHEMBL1795; -.
DR   DrugBank; DB01613; Erythrityl tetranitrate.
DR   DrugBank; DB04899; Nesiritide.
DR   DrugBank; DB11928; Vosoritide.
DR   GuidetoPHARMACOLOGY; 1748; -.
DR   TCDB; 8.A.85.1.2; the guanylate cyclase (gc) family.
DR   GlyGen; P20594; 7 sites.
DR   iPTMnet; P20594; -.
DR   PhosphoSitePlus; P20594; -.
DR   BioMuta; NPR2; -.
DR   DMDM; 113916; -.
DR   EPD; P20594; -.
DR   jPOST; P20594; -.
DR   MassIVE; P20594; -.
DR   MaxQB; P20594; -.
DR   PaxDb; P20594; -.
DR   PeptideAtlas; P20594; -.
DR   PRIDE; P20594; -.
DR   ProteomicsDB; 53766; -. [P20594-1]
DR   ProteomicsDB; 53767; -. [P20594-2]
DR   Antibodypedia; 1647; 245 antibodies from 31 providers.
DR   DNASU; 4882; -.
DR   Ensembl; ENST00000342694.7; ENSP00000341083.2; ENSG00000159899.16. [P20594-1]
DR   GeneID; 4882; -.
DR   KEGG; hsa:4882; -.
DR   MANE-Select; ENST00000342694.7; ENSP00000341083.2; NM_003995.4; NP_003986.2.
DR   UCSC; uc003zyd.4; human. [P20594-1]
DR   CTD; 4882; -.
DR   DisGeNET; 4882; -.
DR   GeneCards; NPR2; -.
DR   HGNC; HGNC:7944; NPR2.
DR   HPA; ENSG00000159899; Low tissue specificity.
DR   MalaCards; NPR2; -.
DR   MIM; 108961; gene.
DR   MIM; 602875; phenotype.
DR   MIM; 615923; phenotype.
DR   MIM; 616255; phenotype.
DR   neXtProt; NX_P20594; -.
DR   OpenTargets; ENSG00000159899; -.
DR   Orphanet; 40; Acromesomelic dysplasia, Maroteaux type.
DR   Orphanet; 329191; Tall stature-long halluces-multiple extra-epiphyses syndrome.
DR   PharmGKB; PA257; -.
DR   VEuPathDB; HostDB:ENSG00000159899; -.
DR   eggNOG; KOG1023; Eukaryota.
DR   GeneTree; ENSGT00940000156985; -.
DR   HOGENOM; CLU_001072_1_3_1; -.
DR   InParanoid; P20594; -.
DR   OMA; AAKSEHY; -.
DR   OrthoDB; 229634at2759; -.
DR   PhylomeDB; P20594; -.
DR   TreeFam; TF106338; -.
DR   BRENDA; 4.6.1.2; 2681.
DR   PathwayCommons; P20594; -.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   SignaLink; P20594; -.
DR   BioGRID-ORCS; 4882; 9 hits in 1104 CRISPR screens.
DR   ChiTaRS; NPR2; human.
DR   GeneWiki; NPR2; -.
DR   GenomeRNAi; 4882; -.
DR   Pharos; P20594; Tbio.
DR   PRO; PR:P20594; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P20594; protein.
DR   Bgee; ENSG00000159899; Expressed in right uterine tube and 184 other tissues.
DR   ExpressionAtlas; P20594; baseline and differential.
DR   Genevisible; P20594; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0042562; F:hormone binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0016941; F:natriuretic peptide receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:UniProtKB.
DR   GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEP:UniProtKB.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IDA:GO_Central.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051447; P:negative regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:1900194; P:negative regulation of oocyte maturation; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0010753; P:positive regulation of cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd07302; CHD; 1.
DR   Gene3D; 3.30.70.1230; -; 1.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR001170; ANPR/GUC.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00211; Guanylate_cyc; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00255; NATPEPTIDER.
DR   SMART; SM00044; CYCc; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   SUPFAM; SSF55073; SSF55073; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00458; ANF_RECEPTORS; 1.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; cGMP biosynthesis; Disease variant;
KW   Disulfide bond; Dwarfism; Glycoprotein; GTP-binding; Lyase; Membrane;
KW   Nucleotide-binding; Osteogenesis; Phosphoprotein; Receptor;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000255"
FT   CHAIN           23..1047
FT                   /note="Atrial natriuretic peptide receptor 2"
FT                   /id="PRO_0000012364"
FT   TOPO_DOM        23..458
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        459..478
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        479..1047
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          513..786
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          861..991
FT                   /note="Guanylate cyclase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   MOD_RES         513
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   MOD_RES         516
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   MOD_RES         518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   MOD_RES         522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P16066"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   MOD_RES         526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   MOD_RES         529
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:20977274"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        161
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        195
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        244
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        277
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        349
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        75..101
FT                   /evidence="ECO:0000250"
FT   DISULFID        439
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305"
FT   DISULFID        448
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305"
FT   VAR_SEQ         964..1047
FT                   /note="PVCAGVVGLKMPRYCLFGDTVNTASRMESNGQALKIHVSSTTKDALDELGCF
FT                   QLELRGDVEMKGKGKMRTYWLLGERKGPPGLL -> KADSHSSPSLHLSQTLPTCFFSK
FT                   GQSVLGLLA (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:10073597"
FT                   /id="VSP_001810"
FT   VARIANT         32
FT                   /note="P -> T (in AMD1; dbSNP:rs28931581)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022583"
FT   VARIANT         76
FT                   /note="S -> P (in SNSK; loss of C-type natriuretic
FT                   peptide-induced signaling; dominant negative effect; loss
FT                   of localization to the plasma membrane; dbSNP:rs796065355)"
FT                   /evidence="ECO:0000269|PubMed:24001744"
FT                   /id="VAR_074678"
FT   VARIANT         110
FT                   /note="R -> C (in SNSK; loss of C-type natriuretic
FT                   peptide-induced signaling; dominant negative effect;
FT                   retained in the endoplasmic reticulum; dbSNP:rs758478717)"
FT                   /evidence="ECO:0000269|PubMed:24471569"
FT                   /id="VAR_074679"
FT   VARIANT         115
FT                   /note="W -> G (in AMD1; markedly deficient activity;
FT                   dbSNP:rs28931582)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022584"
FT   VARIANT         176
FT                   /note="D -> E (in AMD1; dbSNP:rs28929479)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022585"
FT   VARIANT         187
FT                   /note="V -> I (does not affect C-type natriuretic
FT                   peptide-induced signaling; dbSNP:rs768423636)"
FT                   /evidence="ECO:0000269|PubMed:24471569"
FT                   /id="VAR_074680"
FT   VARIANT         232
FT                   /note="M -> I (in dbSNP:rs55747238)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042219"
FT   VARIANT         263
FT                   /note="R -> P (in SNSK; loss of C-type natriuretic
FT                   peptide-induced signaling; dominant negative effect; loss
FT                   of localization to the plasma membrane; dbSNP:rs139036657)"
FT                   /evidence="ECO:0000269|PubMed:24001744"
FT                   /id="VAR_074681"
FT   VARIANT         297
FT                   /note="T -> M (in AMD1; markedly deficient activity;
FT                   dbSNP:rs1313765432)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022586"
FT   VARIANT         338
FT                   /note="Y -> C (in AMD1)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022587"
FT   VARIANT         409
FT                   /note="A -> T (in AMD1)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022588"
FT   VARIANT         413
FT                   /note="G -> E (in AMD1; markedly deficient activity)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022589"
FT   VARIANT         417
FT                   /note="Q -> E (in SNSK; loss of C-type natriuretic
FT                   peptide-induced signaling; dominant negative effect; no
FT                   effect on cell surface expression; dbSNP:rs796065356)"
FT                   /evidence="ECO:0000269|PubMed:24471569"
FT                   /id="VAR_074682"
FT   VARIANT         488
FT                   /note="A -> P (in ECDM; mutant and wild-type alleles have
FT                   similar expression levels; the mutation results in
FT                   increased guanylate cyclase activity; dbSNP:rs587777597)"
FT                   /evidence="ECO:0000269|PubMed:24259409"
FT                   /id="VAR_071875"
FT   VARIANT         655
FT                   /note="R -> C (in ECDM; the mutation results in increased
FT                   guanylate cyclase activity; dbSNP:rs587777596)"
FT                   /evidence="ECO:0000269|PubMed:24057292"
FT                   /id="VAR_071876"
FT   VARIANT         658
FT                   /note="L -> F (in AMD1; no effect on subcellular location;
FT                   changed glycosylation; no effect on C-type natriuretic
FT                   peptide binding; decreased guanylate cyclase activity; loss
FT                   of natriuretic peptide receptor activity; dominant negative
FT                   effect; dbSNP:rs1314542724)"
FT                   /evidence="ECO:0000269|PubMed:17652215,
FT                   ECO:0000269|PubMed:26980729"
FT                   /id="VAR_076481"
FT   VARIANT         708
FT                   /note="Y -> C (in AMD1; no effect on subcellular location;
FT                   changed glycosylation; no effect on C-type natriuretic
FT                   peptide binding; decreased guanylate cyclase activity;
FT                   dbSNP:rs1305337032)"
FT                   /evidence="ECO:0000269|PubMed:15146390,
FT                   ECO:0000269|PubMed:26980729"
FT                   /id="VAR_022590"
FT   VARIANT         771
FT                   /note="Q -> E (in dbSNP:rs5816)"
FT                   /id="VAR_011968"
FT   VARIANT         776
FT                   /note="R -> W (in AMD1; no effect on subcellular location;
FT                   changed glycosylation; no effect on C-type natriuretic
FT                   peptide binding; decreased guanylate cyclase activity;
FT                   dbSNP:rs1303913631)"
FT                   /evidence="ECO:0000269|PubMed:15146390,
FT                   ECO:0000269|PubMed:26980729"
FT                   /id="VAR_022591"
FT   VARIANT         819
FT                   /note="R -> C (in SNSK; loss of C-type natriuretic
FT                   peptide-induced signaling; dominant negative effect; no
FT                   effect on cell surface expression; dbSNP:rs766256429)"
FT                   /evidence="ECO:0000269|PubMed:24001744"
FT                   /id="VAR_074683"
FT   VARIANT         882
FT                   /note="V -> I (in dbSNP:rs55700371)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042220"
FT   VARIANT         882
FT                   /note="V -> M (in ECDM; the mutation results in higher
FT                   guanylate cyclase activity; causes a 15-fold increase in
FT                   basal Vmax; has higher affinity for GTP than wild-type in
FT                   the presence of NPPC; might lead to a structural change
FT                   that locks the enzyme in a conformation mimicking the
FT                   ATP-bound state)"
FT                   /evidence="ECO:0000269|PubMed:22870295,
FT                   ECO:0000269|PubMed:23827346"
FT                   /id="VAR_071877"
FT   VARIANT         957
FT                   /note="R -> C (in AMD1; dbSNP:rs370158184)"
FT                   /evidence="ECO:0000269|PubMed:15146390"
FT                   /id="VAR_022592"
FT   VARIANT         959
FT                   /note="G -> A (in AMD1; no effect on subcellular location;
FT                   changed glycosylation; no effect on C-type natriuretic
FT                   peptide binding; decreased guanylate cyclase activity)"
FT                   /evidence="ECO:0000269|PubMed:15146390,
FT                   ECO:0000269|PubMed:26980729"
FT                   /id="VAR_022593"
FT   MUTAGEN         24
FT                   /note="N->D,Q: Decreased glycosylation. Decreased guanylate
FT                   cyclase activity."
FT                   /evidence="ECO:0000269|PubMed:26980729"
FT   CONFLICT        755
FT                   /note="T -> S (in Ref. 2; BAA81737)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1047 AA;  117022 MW;  817FB74D6B31F7EF CRC64;
     MALPSLLLLV AALAGGVRPP GARNLTLAVV LPEHNLSYAW AWPRVGPAVA LAVEALGRAL
     PVDLRFVSSE LEGACSEYLA PLSAVDLKLY HDPDLLLGPG CVYPAASVAR FASHWRLPLL
     TAGAVASGFS AKNDHYRTLV RTGPSAPKLG EFVVTLHGHF NWTARAALLY LDARTDDRPH
     YFTIEGVFEA LQGSNLSVQH QVYAREPGGP EQATHFIRAN GRIVYICGPL EMLHEILLQA
     QRENLTNGDY VFFYLDVFGE SLRAGPTRAT GRPWQDNRTR EQAQALREAF QTVLVITYRE
     PPNPEYQEFQ NRLLIRARED FGVELGPSLM NLIAGCFYDG ILLYAEVLNE TIQEGGTRED
     GLRIVEKMQG RRYHGVTGLV VMDKNNDRET DFVLWAMGDL DSGDFQPAAH YSGAEKQIWW
     TGRPIPWVKG APPSDNPPCA FDLDDPSCDK TPLSTLAIVA LGTGITFIMF GVSSFLIFRK
     LMLEKELASM LWRIRWEELQ FGNSERYHKG AGSRLTLSLR GSSYGSLMTA HGKYQIFANT
     GHFKGNVVAI KHVNKKRIEL TRQVLFELKH MRDVQFNHLT RFIGACIDPP NICIVTEYCP
     RGSLQDILEN DSINLDWMFR YSLINDLVKG MAFLHNSIIS SHGSLKSSNC VVDSRFVLKI
     TDYGLASFRS TAEPDDSHAL YAKKLWTAPE LLSGNPLPTT GMQKADVYSF GIILQEIALR
     SGPFYLEGLD LSPKEIVQKV RNGQRPYFRP SIDRTQLNEE LVLLMERCWA QDPAERPDFG
     QIKGFIRRFN KEGGTSILDN LLLRMEQYAN NLEKLVEERT QAYLEEKRKA EALLYQILPH
     SVAEQLKRGE TVQAEAFDSV TIYFSDIVGF TALSAESTPM QVVTLLNDLY TCFDAIIDNF
     DVYKVETIGD AYMVVSGLPG RNGQRHAPEI ARMALALLDA VSSFRIRHRP HDQLRLRIGV
     HTGPVCAGVV GLKMPRYCLF GDTVNTASRM ESNGQALKIH VSSTTKDALD ELGCFQLELR
     GDVEMKGKGK MRTYWLLGER KGPPGLL
//
